Recurrent IDH1/2 mutations were detected in gliomas from grade II to IV, showing that IDH1/2 mutated enzymes are needed in gliomagenesis [197,198], hence monitoring D2-HG could be a way of following up the therapy response and early diagnosis of clinical relapse. Here, IDH1 is linked to central nervous system cancer.